Claritev (NYSE:CTEV) Research Coverage Started at Guggenheim

Guggenheim started coverage on shares of Claritev (NYSE:CTEV) in a research report report published on Monday morning, MarketBeat reports. The firm issued a buy rating and a $43.00 price objective on the stock.

A number of other equities analysts have also recently issued reports on CTEV. Wells Fargo & Company set a $33.00 target price on Claritev and gave the stock an “equal weight” rating in a report on Thursday, January 8th. Citigroup dropped their price target on Claritev from $80.00 to $63.00 and set a “buy” rating on the stock in a research note on Friday, January 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Claritev in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Claritev has a consensus rating of “Hold” and an average price target of $46.33.

Claritev Stock Performance

Claritev stock opened at $30.62 on Monday. The firm has a market cap of $506.15 million, a price-to-earnings ratio of -1.46 and a beta of 0.51. Claritev has a 1 year low of $12.86 and a 1 year high of $74.07. The firm’s 50 day moving average price is $42.45 and its two-hundred day moving average price is $51.43.

Insider Buying and Selling at Claritev

In other Claritev news, CEO Travis Dalton purchased 5,290 shares of the business’s stock in a transaction dated Thursday, November 20th. The shares were acquired at an average price of $47.23 per share, for a total transaction of $249,846.70. Following the acquisition, the chief executive officer owned 9,572 shares of the company’s stock, valued at $452,085.56. This trade represents a 123.54% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael Kim purchased 9,600 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were bought at an average price of $38.25 per share, with a total value of $367,200.00. Following the purchase, the executive vice president owned 105,529 shares in the company, valued at $4,036,484.25. This represents a 10.01% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 17,347 shares of company stock worth $710,938 over the last quarter. Company insiders own 8.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. H&F Corporate Investors VIII Ltd. acquired a new stake in shares of Claritev during the 3rd quarter worth approximately $285,988,000. AustralianSuper Pty Ltd acquired a new stake in shares of Claritev in the third quarter valued at $169,605,000. Public Investment Fund bought a new position in shares of Claritev in the third quarter worth about $68,009,000. Vanguard Group Inc. bought a new position in Claritev in the 3rd quarter valued at $27,483,000. Finally, Topline Capital Management LLC acquired a new position in Claritev during the 3rd quarter valued at about $10,711,000. Institutional investors and hedge funds own 87.15% of the company’s stock.

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.